Facebook
Twitter
Telegram
Report an ErrorNurix Therapeutics Financial Statements 2011-2024 | NRIX
Annual Financial Statements Nurix Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
538 M | 548 M | 1.24 B | 1.11 B | - | - | - | - | - | - | - | - | - |
Shares |
54.3 M | 48.6 M | 42.9 M | 31.4 M | - | - | - | - | - | - | - | - | - |
Historical Prices |
9.9 | 11.3 | 28.9 | 32.9 | - | - | - | - | - | - | - | - | - |
Net Income |
-144 M | -180 M | -117 M | -43.2 M | -21.7 M | -9.43 M | - | - | - | - | - | - | - |
Revenue |
77 M | 38.6 M | 29.8 M | 17.8 M | 31.1 M | 37.4 M | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | 17.8 M | - | - | - | - | - | - | - | - | - |
Operating Income |
-155 M | -184 M | -118 M | -65 M | -22.2 M | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-148 M | -179 M | -115 M | -62.8 M | -19.9 M | -6.75 M | - | - | - | - | - | - | - |
Operating Expenses |
232 M | 222 M | 148 M | 82.8 M | 53.4 M | 47.2 M | - | - | - | - | - | - | - |
General and Administrative Expenses |
42.9 M | 38 M | 31.2 M | 16.3 M | 8.33 M | 6.67 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Nurix Therapeutics
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
54.9 M | 48.7 M | 54.4 M | 54.3 M | 54 M | 47.2 M | 50.9 M | 44.9 M | 44.7 M | 44.7 M | 44.4 M | 43.8 M | 38.8 M | 38.7 M | 16.9 M | 3.73 M | 3.54 M | 3.81 M | 3.67 M | 3.43 M | 3.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-41.5 M | - | -37 M | -24.3 M | -40.7 M | - | -45.7 M | -45.4 M | -42.5 M | - | -28.8 M | -26.4 M | -24.3 M | -19.9 M | -18.5 M | 7.58 M | -12.4 M | -13.5 M | -2.43 M | -3.07 M | -2.68 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
16.6 M | - | 18.5 M | 30.7 M | 12.7 M | - | 10.8 M | 11.4 M | 9.62 M | - | 10.3 M | 7.09 M | 5.01 M | 6.69 M | 4.08 M | 4.18 M | 2.86 M | 1.86 M | 10.6 M | 9.44 M | 9.23 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-45.2 M | - | -40 M | -26.8 M | -43 M | - | -46.7 M | -45.7 M | -42.7 M | - | -29 M | -26.4 M | -24.5 M | - | -19.2 M | -13.2 M | -12.6 M | - | -2.61 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-43.2 M | - | - | - | -41.2 M | - | -45.2 M | -44.4 M | -41.8 M | - | -28.3 M | -25.8 M | -23.9 M | - | -18.6 M | -12.7 M | -12.1 M | - | -2.01 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
61.8 M | - | 58.5 M | 57.4 M | 55.6 M | - | 57.5 M | 57.1 M | 52.4 M | - | 39.2 M | 33.5 M | 29.5 M | - | 23.3 M | 17.4 M | 15.4 M | - | 13.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
11.8 M | - | 10.6 M | 11.7 M | 9.82 M | - | 9.75 M | 9.65 M | 9.23 M | - | 8.34 M | 7.51 M | 6.53 M | - | 4.34 M | 3.27 M | 2.45 M | - | 2.18 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency